In vivo studies on evaluation of endophytic fungi extract from Trichoderma viride against cervical cancer

Abstract

Background: The crude ethyl acetate Trichoderma viride extract obtained from Ziziphus mauritiana was initially analyzed by HPLC for identification of major bioactive compounds, and then, it was subjected for in vivo acute and sub-acute toxicity, cervical cancer studies using Wistar albino rats. Result: During acute toxicity studies, animal groups treated with distinct dosage of 2000 mg/kg restrained toxicity signs in tested groups compared to controls for 14 days which established to be secure and non-toxic even at high dose. However, in terms of sub-acute toxicity studies, animals were given with repeated amount of (10 mg/kg, 20 mg/kg and 40 mg/kg) for a period of 28 days along with control group. Upon investigations of hematological, biochemical and histopathological studies repeated dose of 20 mg/kg and 40 mg/kg of T. viride extract found to be normal and no other major changes observed among treated groups. During in vivo studies, after treatment of T. viride extract (40 mg/kg) effectively inhibited the cervical cancer cell growth in DES-treated groups. Through HPLC analysis the major compound ursolic acid and 2,5-piperazinedione were mainly identified. Conclusion: The secondary metabolites of endophytes have been used substantially for the sustainable production of therapeutically important compounds. The limited availability of bioactive principles in plant sources could be surpassed by exploiting the chemical entities in the endophytes. In the present investigation, it has been accomplished that ethyl acetate extract of T. viride was safe at higher and lower dosage could be considered for pharmacological studies from plant may provide an excellent avenue for the discovery of drug candidates against deadly cancer diseases.